If the initial response is adequate, but anti-HBs levels fall to <10 IU/L, a booster dose should be given. Those who do not produce

protective levels (≥10 IU/L) of anti-HBs after two series might be considered for ID vaccination, or the third-generation vaccine. Available therapeutic options include interferons, the nucleoside analogues lamivudine and telbivudine, and the nucleotide analogues adefovir, tenofovir and entecavir. Interferon-α was the first available therapy for chronic HBV infection. Experience in dialysis patients comes from treatment of hepatitis C. In this group, it has been shown that renal failure greatly increases the half-life and area under this website the concentration–time curve.77 Side effects are therefore magnified and consist principally of influenza-like symptoms, myelosuppression and depression. Newer, pegylated interferon is no better tolerated in HD patients.

There are no published series of HBV treatment with interferons in end-stage renal disease (ESRD). There is theoretical concern that they might be less effective given uraemic immune hyporeactivity. Interferons are not recommended in dialysis patients with HBV infection.78 Lamivudine has the longest record of treatment of HBV in dialysis patients, having been introduced in 1998. Lamivudine suppresses viral replication, reduces serum transaminases and improves liver selleckchem Exoribonuclease histology in patients with chronic HBV infection and normal renal function.79 Although lamivudine is excreted via the kidneys, dose reduction permits tolerable prescription in patients

with impaired renal function.80,81 Good results have been obtained in small case series of HBV-infected patients with renal failure82 with one study of 16 HD patients showing that 56% were able to eliminate HBV DNA and 36% were able to clear HBeAg.83 Unfortunately, HBV resistance to lamivudine develops readily in patients with normal renal function. This has been shown to occur in dialysis patients also, with 10 of 26 (39%) HD or renal transplant patients experiencing viral breakthrough after a median 16.5 months of treatment.84 Despite the risk of mutational resistance, lamivudine needs to be continued for prolonged treatment, as withdrawal has been shown to result in occasional serious relapse episodes in patients with normal renal function, particularly if HBeAg seroconversion has only recently occurred, or not occurred at all.85 Adefovir is a nucleotide reverse transcriptase inhibitor initially developed for use in HIV infection. In an early trial, renal toxicity was evident in 60% of HIV patients treated.86 However, the smaller doses used for HBV infection, and a newer preparation (adefovir dipivoxil) have not shown such severe nephrotoxicity. Provided renal function is monitored carefully, adefovir should be acceptable in patients with impaired renal function.